Fig 1: The hub visceral adipocyte-associated DEGs were validated in human hypertrophic cardiomyopathy using single-cell sequencing data. (A) The overall clustering of cells in human hypertrophic cardiomyopathy. (B) The hub genes were validated to be highly expressed in patients with human hypertrophic cardiomyopathy, including OGN, SELL, FOS, NKG7, LOX, HBB, CXCL9, CP and ALOX5.
Fig 2: The effects of FOS and ALOX5 on macrophage senescence. (A) The FOS and ALOX5 related mRNA level in macrophage under hypoxia or normal. (B) The knockdown efficiency of FOS and ALOX5 siRNA. (C) ELISA was performed to determine the SASPs in macrophages under hypoxia and siRNA knockdown. n = 6 per group. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Fig 3: The hub visceral adipocyte-associated DEGs were validated in ischemic cardiomyopathy patients with end-stage heart failure using single-cell sequencing data. (A) The overall clustering of cells in ischemic cardiomyopathy patients with end-stage heart failure. (B) The hub genes were validated to be highly expressed in ischemic cardiomyopathy patients with end-stage heart failure, including OGN, SELL, FOS, NKG7, LOX, HBB, CXCL9, CP and ALOX5.
Fig 4: ROC analysis was performed in human blood samples to investigate the diagnostic value between HFpEF patients and heart failure patients. (A) ROC of OGN, FOS, NKG7 and ALOX5 expression between HFpEF patients and heart failure patients. (B) The joint ROC of OGN, FOS and ALOX5 expression between HFpEF patients and heart failure patients. n = 232 in HFpEF group and n = 32 in heart failure group.
Supplier Page from Abcam for Human c-Fos ELISA Kit